Related Experiment Video
Updated: Aug 20, 2026
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
Chronic myeloid leukemia
N Singhal1, P P Bapsy, K G Babu
1Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bangalore.
Insights
Chronic myeloid leukemia (CML) treatment options are reviewed, including stem cell transplant, chemotherapy, and targeted therapy. Imatinib shows promising results as a new standard of care for CML.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Chronic myeloid leukemia (CML) is a common hematological malignancy.
- CML results from abnormal bcr-abl tyrosine kinase activity due to the Philadelphia chromosome.
- This leads to uncontrolled proliferation of myeloid cells.
Purpose of the Study:
- To discuss current and emerging treatment options for chronic myeloid leukemia.
- To evaluate the efficacy and role of different therapeutic strategies.
- To highlight the significance of targeted therapy in CML management.
Main Methods:
- Review of existing literature on CML treatments.
- Analysis of clinical outcomes for various therapeutic modalities.
- Comparison of traditional therapies with novel targeted agents.
Main Results:
- Allogeneic stem cell transplant is the only curative option for CML.
- Hydroxyurea and Busulfan control leukocyte count but not survival.
- Interferon-based therapies offer functional cure in some patients.
- Imatinib, a targeted oral therapy, demonstrates promising early results.
Conclusions:
- Imatinib represents a significant advancement in CML treatment.
- Targeted therapy with imatinib is considered a new standard of care for CML.
- Further research is ongoing to optimize CML management strategies.
Abstract:
Chronic myeloid leukemia is one of the commonest hematological malignancies seen in clinical practice. It is the result of abnormal and excess cell proliferation due to de-regulated bcr-abl tyrosine kinase activity as a result of Philadelphia chromosome. The present article discusses the various options available to treat the disorder. Allogeneic stem cell transplant remains the gold standard and the only curative option. Hydroxyurea and Busulfan helps in controlling the total leukocyte count but fail to impact on survival. Interferon especially when combined with cytarabine is curative in minority of patients though a substantial number of patients achieve functional cure. Imatinib, a molecular targeted oral therapy, against bcr-abl tyrosine kinase is the latest addition to various treatment options. Early results appear very promising and can be considered as non- transplant standard of care.
More Related Videos
Related Concept Videos
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
01:15Differentiation of Common Myeloid Progenitor Cells